Home › Funds › Venrock Adviser, LLC › DYN
Venrock Adviser, LLC position in DYN
DYNE THERAPEUTICS INC · Health Care
Venrock Adviser, LLC reported holding 2,173,913 shares of DYN (DYNE THERAPEUTICS INC) in its Q2 2026 13F filing — a position valued at US$48.3M, representing 1.46% of its reported portfolio and ranking #13 among its reported holdings. Venrock Adviser, LLC has disclosed DYN holdings in 12 of the last 12 reported quarters, going back to Q3 2023.
Last updated: 2026-10-24 · Source: SEC EDGAR Form 13F-HR
How Venrock Adviser, LLC's DYN position evolved
Venrock Adviser, LLC first disclosed a stake in DYN in Q3 2023 at 2,173,913 shares (US$19.5M). The position peaked in Q3 2024 at 2,173,913 shares, worth US$78.1M. Across 12 filings, Venrock Adviser, LLC held the position steady without any share-count change. The most recent filing (Q2 2026) shows 2,173,913 shares valued at US$48.3M.
Quarter by quarter
| Quarter | Shares | Value | Change |
|---|---|---|---|
| Q3 2023 | 2.17M | $19.48M | New |
| Q4 2023 | 2.17M | $28.91M | Hold |
| Q1 2024 | 2.17M | $61.72M | Hold |
| Q2 2024 | 2.17M | $76.72M | Hold |
| Q3 2024 | 2.17M | $78.09M | Hold |
| Q4 2024 | 2.17M | $51.22M | Hold |
| Q1 2025 | 2.17M | $22.74M | Hold |
| Q2 2025 | 2.17M | $20.70M | Hold |
| Q3 2025 | 2.17M | $27.50M | Hold |
| Q4 2025 | 2.17M | $42.52M | Hold |
| Q1 2026 | 2.17M | $39.41M | Hold |
| Q2 2026 | 2.17M | $48.28M | Hold |
Dots on the line are colored by change type; missing quarters mean no position was reported.
About DYN and 13F data
DYN (DYNE THERAPEUTICS INC) is a Health Care company. 41 other funds we track also report a position in DYN — the largest reported positions include Atlas Venture Life Science Advisors, LLC (US$151.0M), TCG Crossover Management, LLC (US$102.5M), FCPM III SERVICES B.V. (US$85.5M). Under SEC rules, institutional investment managers with over $100M in assets must file Form 13F within 45 days of each quarter-end, disclosing long positions in US-listed equities. The data excludes short positions, most options and foreign holdings, so treat it as a quarterly snapshot rather than a live position.
Other funds holding DYN
- Atlas Venture Life Science Advisors, LLC 6.80M sh · $151.03M · Q2 2026
- TCG Crossover Management, LLC 4.62M sh · $102.50M · Q2 2026
- FCPM III SERVICES B.V. 3.85M sh · $85.47M · Q2 2026
- Vestal Point Capital, LP 3.38M sh · $74.96M · Q2 2026
- ORBIMED ADVISORS LLC 3.24M sh · $71.86M · Q2 2026
- Frazier Life Sciences Management, L.P. 3.15M sh · $70.03M · Q2 2026
- ARMISTICE CAPITAL, LLC 3.09M sh · $68.57M · Q2 2026
- PERCEPTIVE ADVISORS LLC 2.69M sh · $59.73M · Q2 2026
- Logos Global Management LP 2.55M sh · $56.64M · Q2 2026
- Siren, L.L.C. 2.13M sh · $47.29M · Q2 2026
- MPM BioImpact LLC 1.92M sh · $42.69M · Q2 2026
- SAMLYN CAPITAL, LLC 1.75M sh · $38.97M · Q2 2026
More on Venrock Adviser, LLC
FAQ
How long has Venrock Adviser, LLC held DYN?
Venrock Adviser, LLC has disclosed DYN holdings in 12 of the last 12 reported quarters, going back to Q3 2023.
What is Venrock Adviser, LLC's current position in DYN?
As of Q2 2026, Venrock Adviser, LLC holds 2.17M shares of DYN (DYNE THERAPEUTICS INC), valued at $48.28M, representing 1.46% of its reported portfolio and ranking #13.
Has Venrock Adviser, LLC been buying or selling DYN?
In the latest 13F filing (Q2 2026), Venrock Adviser, LLC held unchanged its position in DYN. The position peaked in Q3 2024 at 2.17M shares.
Which other funds hold DYN?
Other major institutional holders of DYN include Atlas Venture Life Science Advisors, LLC, TCG Crossover Management, LLC, FCPM III SERVICES B.V., among 41 funds with disclosed positions.
Where does this data come from?
All figures are computed from SEC Form 13F quarterly filings, which institutional investment managers must file within 45 days of quarter end for long positions of $100,000 or more.